|
|
|
| Clinical effect of Hepatic Artery Injection of Cinobufotalin Combined with Hyperthermic Perfusion Chemotherapy in the Treatment of Primary Hepatocellular Carcinoma |
| CAI Xiang-yang, ZHANG Dong |
| People in Nanjiang County, Sichuan Province 636000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical effect of cinobufotalin injection through hepatic artery combined with hyperthermic perfusion chemotherapy in the treatment of primary hepatocellular carcinoma. 【Methods】Seventy-six patients with primary liver cancer were randomly divided into two groups, 38 cases each. The control group received transcatheter arterial chemoembolization (TACE) after transcatheter arterial infusion chemotherapy, while the observation group received hepatic artery injection of cinobufotalin combined with transcatheter arterial infusion chemotherapy (TACE) three times, one month apart. The efficacy, incidence of adverse reactions, PFS and OS of the two groups were compared.【Results】The disease control rate of the observation group was 63.16% (24/38), higher than that of the control group 41.67% (20/38), but there was no significant difference between the two groups (P>0.05). The incidence of pain in the observation group was 36.84% (14/38), significantly lower than that in the control group 63.16% (24/38), and there was a significant difference between the two groups (P<0.05). The PFS and OS of the observation group were (12.01±2.89) months and (19.32±5.48) months, which were significantly higher than those of the control group (10.03±3.00) months and (15.43 ±4.82) months, and there were significant differences between the two groups (all P<0.05). 【Conclusion】The anti-tumor effect of cinobufotalin intrahepatic artery injection combined with hyperthermic perfusion chemotherapy for primary hepatocellular carcinoma is better, the survival time of patients is prolonged and the pain is alleviated, which is worthy of clinical promotion.
|
|
Received: 27 February 2019
|
|
|
|
|
|
[1] 张慧贤,马向明,付庆江,等.经肝动脉化疗栓塞联合经皮微波消融序贯治疗中晚期肝癌的疗效及预后分析[J]肝脏,2017,22(3):431-434.
[2] 田怀平,杨宇,杨萍,等.华蟾素经肝动脉栓塞灌注给药治疗中晚期原发性肝癌的系统评价[J].环球中医药,2016,9(7):1175-1179.
[3] 李佳,曾宝珠,孙志刚,等.动脉置管灌注华蟾素注射液联合TACE术对原发性肝癌患者HIF-1α、VEGF的影响及其机理探讨[J].世界中医药,2018,13(4):396-399.
[4] 冯宝约,杨莹,王超然,等.华蟾素注射液抗结肠癌移植瘤血管新生的作用研究[J].中国医药导报,2018,15(1):4-7.
[5] 杨光辉,薛涛,李萍,等.华蟾素注射液对原发性肝癌患者血清前白蛋白及血管内皮生长因子的影响[J].中华中医药学刊,2014,32(10):1086-1088.
[6] 邓振云,段浩博.华蟾素联合TACE治疗原发性肝癌临床观察[J].天津中医药,2015,32(2):275-278.
[7] 李淑英,吴申,陈挺松,等.经导管肝动脉栓塞化疗联合华蟾素门静脉灌注治疗中期原发性肝癌疗效研究[J].临床军医杂志,2017,45(4):884-886.
[8] 陈挺松,罗明,李淑英,等.华蟾素注射液门静脉灌注联合TACE治疗肝癌合并门静脉癌栓的疗效及安全性评价[J].实用临床医药杂志,2016,20(1):31-33,58.
[9] 王宁军,芦殿荣,杨柳,等.华蟾素缓解癌性疼痛作用机制的研究进展[J].世界中西医结合杂志,2016,11(5):590-592. |
|
|
|
2019, Vol. 36 
